For the quarter ending 2025-09-30, KYMR had -$222,899K decrease in cash & cash equivalents over the period. -$27,291K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -82,175 | -142,195 |
| Stock-based compensation expense | 15,802 | 29,649 |
| Lease impairment charge | 3,855 | 0 |
| Depreciation and amortization | 2,149 | 4,132 |
| Premiums and discounts on available-for-sale marketable securities | -2,188 | -4,646 |
| Prepaid expenses and other current assets | -266 | 2,305 |
| Accounts receivable | -40,000 | 40,000 |
| Contract asset | 0 | -947 |
| Other non-current assets | -2,153 | -2,725 |
| Accounts payable | -267 | -216 |
| Accrued expenses and other current liabilities | 664 | -6,939 |
| Deferred revenue | -2,764 | 26,424 |
| Operating lease right-of-use assets | -708 | -1,362 |
| Operating lease liabilities | -1,297 | -2,416 |
| Other assets and liabilities | -290 | 106 |
| Net cash used in operating activities | -27,110 | -139,034 |
| Purchase of property and equipment, net | 181 | 1,162 |
| Purchases of investments | 367,558 | 141,907 |
| Maturities of investments | 132,440 | 251,705 |
| Net cash used in investing activities | -235,299 | 108,636 |
| Issuance of common stock and accompanying pre-funded warrants from january 2024 public offering, net of issuance costs of 14.9 million | 0 | 0 |
| Proceeds from issuance of common stock through at-the market sales agreement, net of issuance costs of 1.2 million | 0 | 0 |
| Issuance of common stock and accompanying pre-funded warrants from august 2024 public offering, net of issuance costs of 12.2 million | 237,294 | -237,294 |
| Issuance of common stock and accompanying pre-funded warrants from june 2025 public offering, net of issuance costs of 15.7 million | -272,671 | - |
| Proceeds from stock option exercises | 4,552 | 8,237 |
| Proceeds from employee stock purchase plan | 0 | 1,112 |
| Payments on finance leases | 419 | 659 |
| Net cash provided by financing activities | 39,510 | 245,984 |
| Net increase in cash, cash equivalents and restricted cash | -222,899 | 215,586 |
| Cash and cash equivalents at beginning of period | 126,050 | - |
| Cash and cash equivalents at end of period | 118,737 | - |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)